Merck & Co., Inc. (MRK) — closed signal from September 23, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 22, 2025.
Predicted vs. what happened
What happened
Reached its target in 51 days.
The thesis — published September 23, 2025
Merck just got good news: an easy-to-give Keytruda shot was cleared for many solid tumors, and a partner drug for ovarian cancer earned a fast-track label. The company also teamed up on generative AI to speed discovery. The stock looks out of favor, but buying interest is improving. Over the next 3 months, the price could drift back toward normal as investors rotate into steadier drug makers.
Primary drivers
- Fresh FDA green lights and special status that can speed treatments
- Price looks beaten down, creating room for a steady rebound in coming months
- Investor mood is upbeat even while core numbers are just okay for now
- AI research partnership could help discover new drugs faster and lower costs
How it played out
MRK: target reached in 51 days
On 2025-09-23, Lyra published a short-term MRK thesis at $80.16. It expected 16% growth toward $92.20 over the window. The thesis pointed to fresh FDA green lights and special status, a beaten-down price, improving investor mood, and a research partnership tied to artificial intelligence for drug discovery.
Inside the window, MRK reached the target in 51 days. The peak was $104.95 on 2025-12-22, above the $92.20 target, with a 30.9% peak gain. It ended at $104.72. The thesis played out, and the stock exceeded the stated target.
What happened during the window
On 2025-10-30, Merck reported third-quarter 2025 results that topped expectations, with sales of $17.28 billion and adjusted earnings per share of $2.58. On 2025-11-14, Merck agreed to acquire Cidara Therapeutics in a $9.2 billion all-cash deal tied to Cidara's flu-prevention program.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.